|1.||Terpos, Evangelos: 5 articles (02/2011 - 10/2003)|
|2.||Matsushima, Kouji: 4 articles (05/2010 - 02/2004)|
|3.||Roodman, G David: 4 articles (10/2006 - 05/2003)|
|4.||Cook, D N: 4 articles (10/2001 - 11/2000)|
|5.||Mukaida, Naofumi: 3 articles (09/2015 - 04/2006)|
|6.||Teixeira, Mauro M: 3 articles (04/2011 - 12/2002)|
|7.||Rosenberg, Helene F: 3 articles (01/2009 - 01/2003)|
|8.||Puliti, Manuela: 3 articles (01/2009 - 06/2004)|
|9.||Bistoni, Francesco: 3 articles (01/2009 - 06/2004)|
|10.||Tissi, Luciana: 3 articles (01/2009 - 06/2004)|
08/01/2002 - "These results extend characterization of the cytokine and chemokine cascade required for protection against viral infections in tissues by defining IFN-alpha/beta-dependent mechanisms promoting MIP-1alpha production and the resulting hepatic accumulation of NK cells."
10/01/2001 - "Both WT and MIP-1alpha KO mice subsequently cleared this infection. "
02/01/2013 - "In the present study, we provide evidence to support chemokine CCL3 as one of the vital links between infections and FOXP3 stability in the psoriatic microenvironment. "
12/01/2005 - "In this study, we investigated the role of MIP-1alpha and MCP-1 in the regulation of impaired PKC activity in the early hours (6 h) of infection. "
03/01/2013 - "Cd22(-/-) mice had reduced production of the chemokine CCL3 in the dLNs after infection, suggesting that CD22 affects chemotaxis via controlling chemokine production. "
|2.||Bone Diseases (Bone Disease)
03/01/2007 - "Levels of serum Ctx, OPN, MIP-1alpha, and urine DPD were significantly higher in MM patients with bone disease than in controls (P<0.01). "
10/01/2003 - "This suggests that MIP-1alpha contributes to the pathogenesis of bone disease in MM and possibly in tumour growth, as reflected by its impact on survival."
06/15/2003 - "In addition, we established a strong association (P =.0001) between kappa subgroup expressing high levels of Mip-1alpha and active myeloma bone disease. "
12/01/2001 - "To investigate the role of MIP-1alpha in MM bone disease in vivo, the human MM-derived cell line ARH was stably transfected with an antisense construct to MIP-1alpha (AS-ARH) and tested for its capacity to induce MM bone disease in SCID mice. "
12/01/2001 - "Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease."
11/15/2006 - "MIP-1alpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma."
01/01/2004 - "The recent evidence from our group and others lead to the conclusion that MIP-1alpha is an important mediator in the debilitating bone destruction in multiple myeloma. "
05/15/2003 - "Macrophage inflammatory protein-1alpha (MIP-1alpha) is produced in high concentration by multiple myeloma (MM) cells in about 70% of patients, and MIP-1alpha levels correlate with their disease activity. "
05/15/2003 - "AML-1A and AML-1B regulation of MIP-1alpha expression in multiple myeloma."
05/01/2003 - "Recently, it has been demonstrated that macrophage inflammatory protein 1- alpha (MIP-1 alpha) is crucially involved in the development of osteolytic bone lesions in multiple myeloma (MM). "
05/01/2010 - "Furthermore, MIP-1alpha is also involved in the development of an aggressive phenotype on MCL by stimulating proliferation of these lymphoma cells. "
05/01/2010 - "In the present case, MIP-1alpha, an osteoclast-activating factor produced by mantle lymphoma cells, may contribute to the development of hypercalcemia. "
09/15/2007 - "Here we compare monomeric and dimeric forms of MIP-1alpha and RANTES that target Id to APCs in a mouse B lymphoma (A20) and a multiple myeloma model (MOPC315). "
10/10/2004 - "Infection of A20 B lymphoma cells with a replication-defective adenovirus encoding murine (m) CD40L, but not mIL-2, produces an antigen presentation phenotype with upregulation of MHC Class I/II, induction of B7-1/2 molecules and production of MIL-12 and MIP-1alpha. "
02/01/2004 - "The secretion of osteoclast-activating factors such as MIP-1alpha by the tumor cells (and/or bone marrow stromal cells) might be involved in the etiology of osteolysis and hypercalcemia in some malignant lymphoma cases."
|5.||Hypercalcemia (Milk Alkali Syndrome)
07/01/2004 - "We propose that MIP-1alpha is the clinical hallmark of hypercalcemia in ATL and could be a potentially useful therapeutic target."
07/01/2004 - "High serum MIP-1alpha levels were noted in all 24 ATL patients with hypercalcemia and in 3 of 37 ATL patients without hypercalcemia. "
07/01/2004 - "We propose that serum MIP-1alpha is a clinical hallmark for hypercalcemia in ATL. "
05/01/2010 - "In summary, the present study demonstrated that MIP-1alpha is an important factor in the development of both hypercalcemia and an aggressive phenotype in some types of B-cell lymphoma."
05/01/2010 - "Over-expression of CCL3 MIP-1alpha in a blastoid mantle cell lymphoma with hypercalcemia."
|6.||Chemokine CCL2 (Monocyte Chemoattractant Protein 1)
|7.||Interferon-gamma (Interferon, gamma)
|1.||Drug Therapy (Chemotherapy)
|2.||Combination Drug Therapy (Combination Chemotherapy)
|3.||Highly Active Antiretroviral Therapy (HAART)